FDA Approves Mitapivat for Anemia in Thalassemia Patients 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
CLARIANT enters next phase with GLOBAL BIOENERGIES' renewable isobutene for high-value application
Evry (France), 22 February 2017 - Global Bioenergies (Alternext Paris: ALGBE) announces that, triggered by the successful completion of a first series of tests of its renewable isobutene for a high-value application, Clariant has now ordered a larger batch of renewable isobutene for a second phase of evaluation.
Clariant is a Swiss stock-market listed company with revenues exceeding 5 billion euros in 2015, active in a variety of chemical markets.
In June last year, Global Bioenergies had provided Clariant with a first sample of its renewable isobutene on which Clariant then successfully carried out first chemical tests and analysis.
As a next step, Clariant has now purchased a larger batch of renewable isobutene in order to run more comprehensive tests over several reaction steps as well as functional assays.
Marc Delcourt, CEO of Global Bioenergies comments: "We are pleased to see that Clariant has a concrete vision on how to bring this high-value application of our renewable isobutene into the market. This second phase paves the way for deliveries in commercial scale quantities once the first renewable isobutene commercial plant will be up and running."
About GLOBAL BIOENERGIES
Global Bioenergies is one of the few companies worldwide, and the only one in Europe, that is developing a process to convert renewable resources into hydrocarbons through fermentation. The Company initially focused its efforts on the production of isobutene, one of the most important petrochemical building blocks that can be converted into fuels, plastics, organic glass and elastomers. Global Bioenergies continues to improve the performance of its process, operates an industrial pilot, has started operations at its demo plant in Germany, and is preparing its first full-scale plant through a joint venture with Cristal Union, named IBN-One. The company also replicated its achievement to propylene and butadiene, two members of the gaseous olefins family, key molecules at the heart of petrochemical industry. Global Bioenergies is listed on Alternext, Euronext Paris (FR0011052257 - ALGBE).
Should you like to be kept informed, subscribe to our news feed on
www.global-bioenergies.com
Follow us on Twitter: @GlobalBioenergi
Contact
GLOBAL BIOENERGIES
Frédéric PÂQUES
Chief Operations Officer
Phone: +33 (0)1 64 98 20 50
Email: [email protected]
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/ccfde6b4-c674-4442-bfb1-0a3fe7a8b9ad
